Preview

Problems of Endocrinology

Advanced search

About informative value of very high prolactin levels in patients presenting with prolactin-secreting pituitary macroadenomas (clinical observations)

https://doi.org/10.14341/probl20115743-6

Abstract

The mean blood prolactin level in patients with microprolactinomas is usually 3000-4000 mU/l compared with 10 000-20 000 mU/l in cases presenting with macroprolactinomas. It may be as high as 1 mln mU/l and more in patients with a giant tumour. The measurement of prolactin levels requires laboratory studies of strongly diluted plasma samples. Significant dilution is fraught with erroneous prolactin levels: nevertheless, this approach allows a tendency toward decreasing concentration of prolactin to be revealed which may be important for taking rapid decision concerning the choice of the treatment strategy (either surgical or medicamental) especially in critical situations. A few clinical cases of giant prolactinomas with an unusually high blood prolactin level are described with reference to its dynamics during treatment with cabergoline.

References

1. Casanueva F.F., Molitch M.E., Schlechte J.A. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65: 2: 265-273.

2. Colao A., Di Sarno A., Cappabianca P. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 20: 349: 21: 2023-2033.

3. Colao A., Sarno A.D., Cappabianca P. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003; 148: 3: 325-331.

4. Kars M., Pereira A.M., Smit J.W., Romijn J.A. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med 2009; 20: 4: 387-393. Epub 2008 Dec 30.

5. Schlechte J.A. Prolactinoma. N Engl J Med 2003; 349: 2035-2041.

6. Acharya S.V., Gopal R.A., Menon P.S., Bandgar T.R. Giant prolactinoma and effectiveness of medical management. Endocr Pract 2010; 16: 1: 42-46.

7. Batrinos M.L. Extensive personal experience. Validation of prolactin levels in menstrual disorders and in prolactinomas. Hormones (Athens) 2009; 8: 4: 258-266.

8. Beckers A. СD "Pituitary adenomas" 2007, Graph Med Ltd.

9. Cho E.H., Lee S.A., Chung J.Y., Koh E.H. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci 2009; 24: 5: 874-878.

10. Gillam M.P., Molitch M.E., Lombardi G., Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 5: 485-534. Epub 2006 May 26.

11. Kawabata Y., Ueno Y., Horikawa F., Miyake H. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report. Surg Neurol 2008; 69: 1: 85-88.

12. Petrossians P., de Herder W., Kwekkeboom D. Malignant prolactinoma discovered by D2 receptor imaging. J Clin Endocrinol Metab 2000; 85: 1: 398-401.

13. Schöfl C., Schöfl-Siegert B., Karstens J.H. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary 2002; 5: 4: 261-265.

14. Shimon I., Benbassat C., Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007; 156: 2: 225-231.

15. Shrivastava R.K., Arginteanu M.S., King W.A. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 2002; 97: 299-306.

16. Yang M.Y., Shen C.C., Ho W.L. Treatments of multi-invasive giant prolactinoma. J Clin Neurosci 2004; 11: 1: 70-75.

17. Инструкция к анализатору IMMULITE 2000 (Siemens Healthcare Diagnostics Inc., США).

18. Инструкция к набору реагента MMULITE 2000 PROLACTIN (PIL2KPR-15, 2006-12-29) (Siemens Medical Solutions Diagnostics).

19. Астафьева Л.И., Кадашев Б.А., Калинин П.Л. и др. Клиническая картина, диагностика и результаты первичной медикаментозной терапии больших и гигантских пролактинсекретирующих аденом гипофиза. Вопросы нейрохирургии 2008; 4: 36-39.

20. Астафьева Л.И., Кадашев Б.А., Калинин П.Л. и др. Выбор тактики лечения гигантских пролактинсекретирующих аденом гипофиза. Вопросы нейрохирургии 2009; 2: 23-29.

21. Астафьева Л.И., Кадашев Б.А., Кутин М.А. Изменение размеров пролактинсекретирующих макроаденом гипофиза на фоне терапии агонистами дофамина. "Вестник Российского Научного Центра рентгенрадиологии". 30 сентября 2010 года http://vestnik.rncrr.ru/vestnik/v10/papers/astafieva_v10.htm.


Review

For citations:


Astaf'eva L.I., Kadashev B.A., Tenedieva V.D., Moshkin A.V., Shifrin M.A. About informative value of very high prolactin levels in patients presenting with prolactin-secreting pituitary macroadenomas (clinical observations). Problems of Endocrinology. 2011;57(4):3-6. https://doi.org/10.14341/probl20115743-6

Views: 511


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)